Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

INTRODUCTION: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine clinical practice. We assessed whether DrotAA is cost-effective in...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sadique, M Zia, Grieve, Richard, Harrison, David A, Cuthbertson, Brian H, Rowan, Kathryn M
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2011
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3334774/
https://ncbi.nlm.nih.gov/pubmed/21943177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc10468
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires